Marinus Pharmaceuticals Inc [MRNS] stock is trading at $0.32, down -2.56%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MRNS shares have gain 11.76% over the last week, with a monthly amount drifted -82.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Marinus Pharmaceuticals Inc [NASDAQ: MRNS] stock has seen the most recent analyst activity on September 23, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $6 for it. Previously, Ladenburg Thalmann downgraded its rating to Neutral on August 14, 2024. On April 16, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $2 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $3 on April 15, 2024. Oppenheimer downgraded its rating to a Perform and reduced its price target to $9 on August 11, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on January 20, 2023, and assigned it a price target of $23. In a note dated September 30, 2020, Truist initiated an Buy rating and provided a target price of $35 on this stock.
Marinus Pharmaceuticals Inc [MRNS] stock has fluctuated between $0.26 and $11.26 over the past year. Currently, Wall Street analysts expect the stock to reach $3.67 within the next 12 months. Marinus Pharmaceuticals Inc [NASDAQ: MRNS] shares were valued at $0.32 at the most recent close of the market. An investor can expect a potential return of 1046.88% based on the average MRNS price forecast.
Analyzing the MRNS fundamentals
Marinus Pharmaceuticals Inc [NASDAQ:MRNS] reported sales of 30.26M for the trailing twelve months, which represents a growth of 32.48%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -4.4%, Pretax Profit Margin comes in at -4.93%, and Net Profit Margin reading is -4.93%. To continue investigating profitability, this company’s Return on Assets is posted at -1.71, Equity is -79.35 and Total Capital is -2.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3170 points at the first support level, and at 0.3099 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3319, and for the 2nd resistance point, it is at 0.3397.
Ratios To Look Out For
For context, Marinus Pharmaceuticals Inc’s Current Ratio is 2.28. In addition, the Quick Ratio stands at 2.15 and the Cash Ratio stands at 1.8. Considering the valuation of this stock, the price to sales ratio is 0.59.
Transactions by insiders
Recent insider trading involved Pfanstiel Steven, CFO AND COO, that happened on Aug 05 ’24 when 4657.0 shares were sold. CHIEF COMMERCIAL OFFICER, Shafer Christina completed a deal on Aug 05 ’24 to sell 3820.0 shares. Meanwhile, SVP, GEN. COUNSEL & CORP. SEC. MANNING MARTHA E sold 3621.0 shares on Aug 05 ’24.
